Nicholas W. Fischer
Toronto, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome.
Journal: iScience
Published: June 11, 2024
Clinical impact of TP53 functional mutations in patients with metastatic colorectal cancer treated with bevacizumab and chemotherapy.
Journal: The oncologist
Published: April 06, 2024
TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroup.
Journal: Nature communications
Published: February 12, 2024
Cell-free DNA from germline TP53 mutation carriers reflect cancer-like fragmentation patterns.
Journal: Nature communications
Published: September 11, 2023
Emerging insights into ethnic-specific TP53 germline variants.
Journal: Journal of the National Cancer Institute
Published: February 14, 2023
TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy.
Journal: Cancers
Published: June 10, 2020
Association Between the Oligomeric Status of p53 and Clinical Outcomes in Li-Fraumeni Syndrome.
Journal: Journal of the National Cancer Institute
Published: November 09, 2017
A Synthetic Cross-Species CD200R1 Agonist Suppresses Inflammatory Immune Responses In Vivo.
Journal: Molecular therapy. Nucleic acids
Published: September 10, 2017
Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells.
Journal: International journal of cancer
Published: July 19, 2017
p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis.
Journal: Cell cycle (Georgetown, Tex.)
Published: October 19, 2016
Last Updated: 09/26/2026